Clinical Trials | November 10, 2025
Relmada gains FDA backing for two registrational trials and reports 92% response with NDV-01 in bladder Cancer
Relmada expects to initiate its Phase 3 program in the first half of 2026
Relmada expects to initiate its Phase 3 program in the first half of 2026
Venus Remedies now has 29 active product approvals in Vietnam alone
Solara Active Pharma Sciences has reported total income of Rs. 314.03 crore during the period ended September 30, 2025
SMS Pharmaceuticals has reported total income of Rs. 243.86 crore during the period ended September 30, 2025
Sun Pharmaceutical Industries has reported total income of Rs. 14,948.23 crore during the period ended September 30, 2025
Olaparib is indicated for the treatment of certain types of ovarian, breast, pancreatic, and prostate cancers
The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Sprycel Tablets
Sumatriptan injection is indicated in adults for the acute treatment of migraine
A bio-analytical Remote Regulatory Assessment was also conducted from October 30 to November 7, 2025, and concluded with no observations
The discussions come as part of the administration’s broader efforts to drive down drug prices and increase patient access to essential therapies
Subscribe To Our Newsletter & Stay Updated
